Comparative study of 18FFDG PET/CT and 99TcmMDP bone scintigraphy in detecting multiple myeloma bone destruction

doi:10.3760/cma.j.issn.1673-422X.2013.12.019

Abstract

Abstract: ObjectiveTo explore the application value of 18Ffluorodeoxyglucose positron emission tomography/computed tomography (18FFDG PET/CT) and 99Tcmmethylene diphosphonate (99TcmMDP) bone scintigraphy for detecting bone destruction in multiple myeloma (MM). Methods18FFDG PET/CT and 99TcmMDP bone scintigraphy results of 27 MM patients were analyzed retrospectively. Inspection areas checked by magnetic resonance imaging (MRI) and Xray were the limited scopes. The location and number of bone destruction were recorded, and the maximal standardized uptake value (SUVmax) was measured simultaneously. The results were comparatively analyzed. Diagnostic certainty regarding the presence or absence of bone destruction was evaluated according to the reference standard consisting of MRI and Xray. ResultsA total of 235 lesions were found according to the reference standard. Of these, 227 lesions (97%) were identified by 18FFDG PET/CT, whereas 187 lesions (80%) were identified by bone scintigraphy, with a significant statistical difference (χ2=32.43, P＜0.05). SUVmax was 8.3±1.7 (4.3 to 18.9). The discovery rates of bone fracture of 18FFDG PET/CT and bone scintigraphy were 100% (97/97) and 90% (87/97), and there was a significant statistical difference between them (χ2=78.09, P＜0.05). Conclusion18FFDG PET/CT is a possible method to detect bone lesions in patients with MM, and is better than 99TcmMDP bone scintigraphy.

Key words: Multiple myeloma, Positronemission tomography, Tomography, emissioncomputed, singlephoton, Fluorodeoxyglucose F18, Technetium Tc 99m medronate

WU Zhi-Xing, 吕Kuan , ZHANG Ke, KONG Xiang-Hui, GUO Hui-Min. Comparative study of 18FFDG PET/CT and 99TcmMDP bone scintigraphy in detecting multiple myeloma bone destruction[J]. Journal of International Oncology, 2013, 40(12): 940-944.

References

［1］徐岚, 王焰, 吴文, 等. 多发性骨髓瘤182例临床分析. 中华医学杂志, 2010, 90(14): 972977. ［2］戴颖钰, 郭亮. 肋骨常见病变的X线及CT诊断. 中国血液流变学杂志, 2009, 19(2): 309311. ［3］ Haznedar R, Aki SZ, Akdemir OU, et al. Value of 18Ffluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging, 2011, 38(6): 10461053. ［4］ Fonti R, Salvatore B, Quarantelli M, et al. 18FFDG PET/CT, 99TcmMIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med, 2008, 49(2): 195200. ［5］ Evangelista L, Panunzio A, Polverosi R, et al. Early bone marrow metastasis detection: the additional value of FDGPET/CT vs. CT imaging. Biomed Pharmacother, 2012, 66(6): 448453. ［6］ Mulligan M, Chirindel A, Karchevsky M. Characterizing and predicting pathologic spine fractures in myeloma patients with FDG PET/CT and MR imaging. Cancer Invest, 2011, 29(5): 370376. ［7］ Fonti R, Larobina M, Del VS, et al. Metabolic tumor volume assessed by 18FFDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med, 2012, 53(12): 18291835. ［8］宋建华, 赵晋华, 陈香, 等. 多发性骨髓瘤的18FFDG PET/CT鉴别诊断及疗效评估价值. 中国医学计算机成像杂志, 2011, 17(1): 7074. ［9］ Elliott BM, Peti S, Osman K, et al. Combining FDGPET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma. Eur J Haematol, 2011, 86(4): 289298. ［10］ Derlin T, Peldschus K, Münster S, et al. Comparative diagnostic performance of 18FFDG PET/CT versus wholebody MRI for determination of remission status in multiple myeloma after stem cell transplantation. Eur Radiol, 2013, 23(2): 570578. ［11］ Derlin T, Weber C, Habermann CR, et al. 18FFDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. Eur J Nucl Med Mol Imaging, 2012, 39(3): 493500. ［12］ D′Sa S, Abildgaard N, Tighe J, et al. Guidelines for the use of imaging in the management of myeloma. Br J Haematol, 2007, 137(1): 4963. ［13］ Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia, 2009, 23(9): 15451556.

[1]	Ren Lu, Xie Xiaoli, Zhang Kun, Wang Lijuan. Effects and mechanisms of dihydroartemisinin combined with carfilzomib on the activity， proliferation， and apoptosis of multiple myeloma cells [J]. Journal of International Oncology, 2024, 51(3): 129-136.
[2]	Zhang Yuxiao, Zhang Liansheng, Li Lijuan. Research status and application prospect of a novel immune checkpoint TIGIT in the immunotherapy of multiple myeloma [J]. Journal of International Oncology, 2023, 50(2): 122-125.
[3]	Zhao Jianhao, Duan Yanchao. Research progress in the pathogenesis of extramedullary disease in multiple myeloma [J]. Journal of International Oncology, 2023, 50(1): 55-59.
[4]	Gao Shan, Lu Minqiu, Shi Lei, Chu Bin, Fang Lijuan, Xiang Qiuqing, Wang Yutong, Ding Yuehua, Bao Li. Clinical efficacy and safety of ixazomib-based therapy in the treatment of relapsed or refractory multiple myeloma [J]. Journal of International Oncology, 2022, 49(5): 286-291.
[5]	Sun Ruijie, Shan Ningning. Immune, targeted therapy and related issues of relapsed/refractory multiple myeloma [J]. Journal of International Oncology, 2021, 48(6): 381-384.
[6]	Hou Yuanmei, Li Junpeng. Recent advances in immunotherapy for relapsed or refractory multiple myeloma [J]. Journal of International Oncology, 2020, 47(12): 765-768.
[7]	Yao Yixuan, Wang Huan, Xia Jun, Wang Jing, Sun Chao, Sun Hongli, Zhou Xin. Correlations between peripheral absolute lymphocyte count and clinicopathological characteristics of the elderly patients with multiple myeloma and its prognosis [J]. Journal of International Oncology, 2018, 45(6): 347-351.
[8]	Yuan Qing, Chen Shaoshui. Application of circulating microRNAs in multiple myeloma [J]. Journal of International Oncology, 2018, 45(1): 53-.
[9]	Liu Xiaolan, Guan Tao, Su Liping. Detection and clinical application of minimal residual disease in multiple myeloma [J]. Journal of International Oncology, 2018, 45(1): 56-.
[10]	LI Si-Yuan, XU Wen-Gui, TONG Guan-Sheng, ZHANG Li, WEN Zhe. Value of 18FFDG PET/CT in evaluation of curative effect and progressionfree survival on lymphoma [J]. Journal of International Oncology, 2017, 44(5): 361-365.
[11]	Wu Yuan, Liu Xiaolan, Su Liping. The clinical utility of 18F-FDG PET-CT for detection of bone marrow infiltration in lymphoma [J]. Journal of International Oncology, 2016, 43(8): 634-637.
[12]	Luo Li, Shen Qun, Xi Xuping, Liu Feng, Xiao Feng.. Application of 18FFDG PETCT in nasopharyngeal carcinoma [J]. Journal of International Oncology, 2016, 43(8): 615-618.
[13]	WANG Wei-Yuan, GUO Dong-Mei, HAN Tian-Jie, TENG Qing-Liang. Role and treatment strategy of hypoxia in the pathogenesis of multiple myeloma [J]. Journal of International Oncology, 2016, 43(7): 552-554.
[14]	Yue Jin, Su Liping. Diagnosis and prognosis evaluation of 18FFDG PET/CT in bone marrow infiltration of lymphoma [J]. Journal of International Oncology, 2016, 43(5): 395-397.
[15]	ZHAO Xiang-Rong, ZHANG Yong, YU Yong-Hua. The advances in diagnosis and treatment of nonsmall cell lung cancer with PET-CT [J]. Journal of International Oncology, 2016, 43(2): 133-.